Sustained-Release Hydromorphone Microparticles Produced by Supercritical Fluid Polymer Encapsulation

J Pharm Sci. 2019 Feb;108(2):811-814. doi: 10.1016/j.xphs.2018.09.021. Epub 2018 Sep 26.

Abstract

Chronic cancer pain remains prevalent and severe for many patients, particularly in those with advanced disease. The effectiveness of analgesic/adjuvant drug treatments in routine practice has changed little in the last 30 years. To address these issues herein, we have developed sustained-release poly(lactic-co-glycolic acid) microparticles of hydromorphone for intrathecal injection aimed at producing prolonged periods of satisfactory analgesia in patients, as a novel strategy for alleviation of intractable cancer-related pain. These hydromorphone-loaded microparticles were produced successfully using organic solvent-free supercritical fluid polymer encapsulation. Drug loading at 9.2% and encapsulation efficacy at 92% were achieved for particles in the desired size range (20-45 μm) with sustained release over a 5-week period in vitro.

Keywords: chronic cancer pain; intrathecal injection; microparticles; poly(lactic-co-glycolic acid); satisfactory analgesia; supercritical CO(2).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analgesics, Opioid / administration & dosage*
  • Analgesics, Opioid / chemistry
  • Cancer Pain / drug therapy
  • Delayed-Action Preparations / chemistry*
  • Drug Compounding / methods
  • Drug Liberation
  • Humans
  • Hydromorphone / administration & dosage*
  • Hydromorphone / chemistry
  • Injections, Spinal
  • Polylactic Acid-Polyglycolic Acid Copolymer / chemistry*

Substances

  • Analgesics, Opioid
  • Delayed-Action Preparations
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Hydromorphone